Slide 1: Target therapy matched to genomic alterations in recurrent IDH wildtype glioblastoma
Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma A real-life cohort analysis from Veneto Institute of Oncology, Padua (Italy) Giulia Cerretti *, Marta Padovan, Chiara De Toni, Marta Maccari, Alberto Bosio, Mario Caccese, Martina Corrà, Ilaria Cestona
Slide 2: Declaration of Interests
DECLARATION OF INTERESTS Nothing to declare Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
Slide 3: Background
Background New molecular technologies allow the identification of alterations within hundreds of cancer-related genes and can guide a personalized strategy in cancer treatment. There are only few data available regarding target therapy efficacy and feasibility for patients with glioblastoma. Ima
Slide 4: Methods
Methods Nature of the study Inclusion criteria Targetable alteration Treatment Our retrospective study Newly diagnosed or Molecular alterations Target therapy was given involved all patients with recurrent GBM were classified into as: IDH wildtype GBM treated (according to WHO categories of targetab
Slide 5: Methods
Methods BRAF V600E IB NRTK 1-2-3 fusion Ic FGFR 1-2-3 alteration IB ROS1 fusion rN MET fusion - 1A amplification PIK3CA mutation MA PTEN loss - mutation IA dabrafenib/trametinib larotrectinib erdafitinib entrectinib capmatinib; APL-101 alpelisib ipatasertib +/- atezolizumab ESCAT Scale is from: Mate
Slide 6: Methods
Methods Overall response Intra-patient Endpoints evaluation response evaluation Efficacy of target Responses were PFS2/PFS1 ratio was therapies: assessed by brain MRI calculated, as: ORR every 6–8 weeks DCR according to RANO PFS (Response Assessment OS in Neuro-Oncology) criteria. Toxicity of target
Slide 7: Results
Results Out of the 37 patients who received TT, 21 were male; ECOG performance status was ≤ 1 in 31 patients. Median line of treatment was 3 (2 – 7). Patients treated with Best Response (RANO criteria) Gene alteration Targeted therapy ORR DCR targeted therapy CR PR SD PD BRAF V600E 9 dabrafenib/
Slide 8: Results
Results Out of the 37 patients who received TT, 21 were male; ECOG performance status was ≤ 1 in 31 patients. Median line of treatment was 3 (2 – 7). Patients treated with Best Response (RANO criteria) Gene alteration Targeted therapy ORR DCR targeted therapy CR PR SD PD BRAF V600E 9 dabrafenib/
Slide 9: Results
Results Out of the 37 patients who received TT, 21 were male; ECOG performance status was ≤ 1 in 31 patients. Median line of treatment was 3 (2 – 7). Patients treated with Best Response (RANO criteria) Gene alteration Targeted therapy ORR DCR targeted therapy CR PR SD PD BRAF V600E 9 dabrafenib/
Slide 10: Results
Results Progression-free survival (months)
Slide 11: Results
Results PFS-ratio > 1.3 might suggest a clinical benefit, according to previous literature. PFS-ratio > 1.3 was achieved in 27% of overall cohort and in 44% of patients treated with dabrafenib/trametinib.
Slide 12: Conclusions
Conclusions Target therapy Present perspectives Future trends In selected cases of Our findings endorsed We reported interesting patients with recurrent the efficacy of results targeting MET, glioblastoma, target anti-BRAF / anti-MEK ROS1, NTRK and therapy is a viable treatment for BRAF FGFR, option
Slide 13: IOV Oncology 1 Neuro-Oncology Group
IOV Oncology 1 IOV Statistics Neurology Az. Univ IOV Pharmacy Unit Neuro-Oncology Group Gian Luca De Salvo Padua Marina Coppola Giuseppe Lombardi Chiara De Toni Maurizio Corbetta Francesca Di Sarra Marta Padovan IOV Data management Alessandro Salvalaggio Anna Parlantzas Mario Caccese Martina Corrà M